Constantine Alifrangis, Ciara O'Hanlon-Brown, Mark Tuthill, Jonathan Waxman. (2012) New drugs for prostate cancer. BJU International 109 , 1801-1806 /Alifrangis C, O'Hanlon-Brown C, Tuthill M et al: New drugs for prostate cancer. BJU Int 2012; 109: 1801....
Prostate cancerNew drugs in prostate cancerArmstrong, Andrew J.; Carducci, Michael A.Abstract Purpose of review: The survival of hormone-refractory metastatic prostate cancer patients has improved with the use of docetaxel-based chemotherapy. The survival benefits, however, are modest suggesting that ...
Scientists at Bath, funded by Prostate Cancer UK with support from the Movember Foundation, have developed an innovative tool to test potential drugs forprostate cancer. The researchers hope this technique will help speed up the development of new treatments for the disease, the most common form o...
After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer a chronic illness instead of a terminal disease, a leading Colorado prostate cancer expert says. "It's not just chemotherapy. The drugs have different and innovative methods of action. One is...
A new model that compares costs and outcomes of drugs used in the treatment of castrate-resistant prostate cancer has concluded that generic docetaxel and abiraterone (Zytiga) offer better value than cabazitaxel (Jevtana) and sipuleucel-T (Provenge). The finding was reported by Helmy Guirgis, MD...
Chemotherapy and New Drugs in Prostate Cancer 来自 Ingenta 喜欢 0 阅读量: 11 作者: Nicolas Mottet 摘要: is no evidence of superiority of one therapeutic modality over the others as no formal head-to- head comparison is available. Furthermore, the inclusion criteria are different across the...
in cancer development ofETSfusion-negative cancers. Computational chemogenomic (canSAR) analysis of prostate cancer mutations identified 11 targets of approved drugs, 7 targets of investigational drugs, and 62 targets of compounds that may be active and should be considered candidates for future clinical...
Returning from ASCO 2024, Sandy Srinivas, MD, discusses the results from the PSMAfore trial, which compared lutetium-177(177Lu)-PSMA-617 with alternate androgen receptor pathway inhibitors [ARPIs] in patients with metastatic castration-resistant prostate cancer. The trial showed that177Lu-PSMA-617...
which plays a critical role in development of resistance to contemporary androgen receptor-target therapies. The scientists found that prostate cancer patients with elevated GPR158 expression experienced recurrence of prostate cancer. The GPR158 protein is a likely target for new prostate cancer drugs. ...
" could lead to a more efficient therapeutic approach for the treatment of castration-resistant prostate cancer. "Abiraterone, a CYP17A1 inhibitor, has been one the biggest breakthough drugs to combat advanced cancer. But resistance to this drug is still a major problem. Having a second line ...